{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T09:26:38Z","timestamp":1793957198041,"version":"4.8.0"},"reference-count":21,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:00:00Z","timestamp":1790726400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100014751","name":"Neuraxpharm","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014751","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.msard.2026.107953","type":"journal-article","created":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T15:20:44Z","timestamp":1790781644000},"page":"107953","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Long-term comparative outcomes in relapse activity and disability progression among anti-CD20 therapies in relapsing multiple sclerosis: An unanchored matching-adjusted indirect comparison"],"prefix":"10.1016","volume":"115","author":[{"given":"Ralf","family":"Gold","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9298-6393","authenticated-orcid":false,"given":"Amir","family":"Ansaripour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaus","family":"Schmierer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Barnett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans Peter","family":"Hartung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bassem","family":"Yamout","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerome","family":"de Seze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krzysztof","family":"Selmaj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego","family":"Centonze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolaos","family":"Grigoriadis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehdi","family":"Javanbakht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hari","family":"Miskin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas B.","family":"Schmitt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary","family":"Cutter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2026.107953_bib0001","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/s40265-024-02011-w","article-title":"Drugs targeting CD20 in multiple sclerosis: pharmacology, efficacy, safety, and tolerability","volume":"84","author":"Carlson","year":"2024","journal-title":"Drugs"},{"key":"10.1016\/j.msard.2026.107953_bib0002","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.2517-6161.1972.tb00899.x","article-title":"Regression models and life-tables","volume":"34","author":"Cox","year":"1972","journal-title":"J. R. Stat. Soc. Ser. B"},{"key":"10.1016\/j.msard.2026.107953_bib0003","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1001\/jamaneurol.2026.0007","article-title":"Five years of ublituximab in multiple sclerosis: ULTIMATE I and II open-label extension study","volume":"83","author":"Cree","year":"2026","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.msard.2026.107953_bib0004","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1093\/biomet\/81.3.515","article-title":"Proportional hazards tests and diagnostics based on weighted residuals","volume":"81","author":"Grambsch","year":"1994","journal-title":"Biometrika"},{"key":"10.1016\/j.msard.2026.107953_bib0005","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/1471-2288-12-9","article-title":"Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves","volume":"12","author":"Guyot","year":"2012","journal-title":"BMC Med. Res. Methodol."},{"key":"10.1016\/j.msard.2026.107953_bib0006","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1056\/NEJMoa1917246","article-title":"Ofatumumab versus teriflunomide in multiple sclerosis","volume":"383","author":"Hauser","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.msard.2026.107953_bib0007","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1056\/NEJMoa1601277","article-title":"Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis","volume":"376","author":"Hauser","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.msard.2026.107953_bib0008","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1007\/s40120-025-00784-0","article-title":"Five-year safety and efficacy outcomes with ofatumumab in patients with relapsing multiple sclerosis","volume":"14","author":"Hauser","year":"2025","journal-title":"Neurol. Ther."},{"key":"10.1016\/j.msard.2026.107953_bib0009","doi-asserted-by":"crossref","first-page":"E1854","DOI":"10.1212\/WNL.0000000000010376","article-title":"Five years of ocrelizumab in relapsing multiple sclerosis: OPERA studies open-label extension","volume":"95","author":"Hauser","year":"2020","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2026.107953_bib0010","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.msard.2014.08.005","article-title":"Natalizumab reduces relapse clinical severity and improves relapse recovery in MS","volume":"3","author":"Lublin","year":"2014","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2026.107953_bib0011","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2024.1479476","article-title":"Comparative efficacy and tolerability of ublituximab vs. other monoclonal antibodies in the treatment of relapsing multiple sclerosis: a systematic review and network meta-analysis of randomized trials","volume":"15","author":"Moloney","year":"2024","journal-title":"Front. Neurol."},{"key":"10.1016\/j.msard.2026.107953_bib0012","unstructured":"NICE, 2013. Guide to the methods of technology appraisal 2013 [WWW Document]. Process methods. URL https:\/\/www.nice.org.uk\/process\/pmg9\/resources\/guide-to-the-methods-of-technology-appraisal-2013-pdf-2007975843781 (accessed 9.10.21)."},{"key":"10.1016\/j.msard.2026.107953_bib0013","unstructured":"Phillippo, D.M.; Ades, A.E.; Dias, S.; Palmer, S.; Abrams, K.R.., Welton, N.., 2016. NICE DSU technical support document 18: methods for population-adjusted indirect comparisons in submission to NICE."},{"key":"10.1016\/j.msard.2026.107953_bib0014","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1001\/jamaneurol.2025.4085","article-title":"Seizure frequency trends over time in treatment-resistant focal epilepsy","volume":"82","author":"Potnis","year":"2025","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.msard.2026.107953_bib0015","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1002\/jrsm.1511","article-title":"Methods for population adjustment with limited access to individual patient data: a review and simulation study","volume":"12","author":"Remiro-Az\u00f3car","year":"2021","journal-title":"Res. Synth. Methods"},{"key":"10.1016\/j.msard.2026.107953_bib0016","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1186\/1471-2288-13-152","article-title":"Restricted mean survival time: an alternative to the hazard ratio for the design and analysis of randomized trials with a time-to-event outcome","volume":"13","author":"Royston","year":"2013","journal-title":"BMC Med. Res. Methodol."},{"key":"10.1016\/j.msard.2026.107953_bib0017","doi-asserted-by":"crossref","DOI":"10.57264\/cer-2023-0016","article-title":"Comparative efficacy of therapies for relapsing multiple sclerosis: a systematic review and network meta-analysis","volume":"12","author":"Samjoo","year":"2023","journal-title":"J. Comp. Eff. Res."},{"key":"10.1016\/j.msard.2026.107953_bib0018","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1056\/NEJMoa2201904","article-title":"Ublituximab versus Teriflunomide in relapsing multiple sclerosis","volume":"387","author":"Steinman","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.msard.2026.107953_bib0019","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1212\/WNL.96.15_supplement.4494","article-title":"Efficacy and safety of ublituximab versus teriflunomide in relapsing multiple sclerosis: results of the phase 3 ULTIMATE I and II trials (4494)","volume":"96","author":"Steinman","year":"2021","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2026.107953_bib0020","unstructured":"Therneau, T.M., 2026. A package for survival analysis in R [WWW Document]. R Packag. version 3.8-6. URL https:\/\/cran.r-project.org\/package=survival."},{"key":"10.1016\/j.msard.2026.107953_bib0021","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","article-title":"Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria","volume":"17","author":"Thompson","year":"2018","journal-title":"Lancet Neurol."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034826009880?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034826009880?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T08:38:35Z","timestamp":1793954315000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034826009880"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":21,"alternative-id":["S2211034826009880"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2026.107953","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long-term comparative outcomes in relapse activity and disability progression among anti-CD20 therapies in relapsing multiple sclerosis: An unanchored matching-adjusted indirect comparison","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2026.107953","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"107953"}}